Volume 12, Issue 1 (Feb 2024)
Res Mol Med (RMM) 2024, 12(1): 39-48 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tamizifar B, Kassaian N, khorasani M R, Sabzali S, Shahzamani K, Adibi P. Evaluating COVID-19 Vaccine Side Effects in Patients With Inflammatory Bowel Disease: A Case-control Study in Iran. Res Mol Med (RMM) 2024; 12 (1) :39-48
URL: http://rmm.mazums.ac.ir/article-1-575-en.html
URL: http://rmm.mazums.ac.ir/article-1-575-en.html
Babak Tamizifar1 
, Nazila Kassaian2 , Marzieh Rahim Khorasani3 , Somaieh Sabzali4 , Kiana Shahzamani5 , Peyman Adibi6
, Nazila Kassaian2 , Marzieh Rahim Khorasani3 , Somaieh Sabzali4 , Kiana Shahzamani5 , Peyman Adibi6
1- Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. , Babaktamizifar@gmail.com
2- Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
3- Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
4- Department of Biology, Faculty of Basic Sciences, Lorestan University, Khorramabad, Iran.
5- Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
6- Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
2- Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
3- Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
4- Department of Biology, Faculty of Basic Sciences, Lorestan University, Khorramabad, Iran.
5- Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
6- Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract: (1163 Views)
Background: The COVID-19 pandemic has presented unique challenges for individuals with inflammatory bowel disease (IBD), a group already at increased risk due to altered immune function and immunosuppressive treatments. While vaccines remain the most effective tool for controlling the pandemic, concerns about their safety and potential to worsen IBD symptoms have led to hesitancy among patients. This study explored the side effects of COVID-19 vaccines in IBD patients compared to healthy individuals.
Materials and Methods: This case-control study was conducted in Isfahan, Iran, from September to December 2021. The study involved 86 IBD patients and 91 healthy participants who had received at least one dose of a COVID-19 vaccine. Information about vaccine-related side effects was gathered through interviews, and statistical methods were used to identify any significant differences between the two groups.
Results: The findings showed that vaccine side effects were mild and temporary in both groups, with no significant differences in overall frequency (70% in IBD patients vs 67% in healthy controls). Common side effects included localized pain, fatigue, headaches, and fever, all of which resolved quickly. Notably, no IBD patients reported a flare of their condition after vaccination. Despite this, fewer IBD patients opted for second or third doses, likely due to lingering concerns about adverse effects.
Conclusion: COVID-19 vaccination is safe for IBD patients, with side effects similar to or less frequent than those seen in the general population. Clear communication and targeted strategies are needed to alleviate vaccine hesitancy in this vulnerable group.
Materials and Methods: This case-control study was conducted in Isfahan, Iran, from September to December 2021. The study involved 86 IBD patients and 91 healthy participants who had received at least one dose of a COVID-19 vaccine. Information about vaccine-related side effects was gathered through interviews, and statistical methods were used to identify any significant differences between the two groups.
Results: The findings showed that vaccine side effects were mild and temporary in both groups, with no significant differences in overall frequency (70% in IBD patients vs 67% in healthy controls). Common side effects included localized pain, fatigue, headaches, and fever, all of which resolved quickly. Notably, no IBD patients reported a flare of their condition after vaccination. Despite this, fewer IBD patients opted for second or third doses, likely due to lingering concerns about adverse effects.
Conclusion: COVID-19 vaccination is safe for IBD patients, with side effects similar to or less frequent than those seen in the general population. Clear communication and targeted strategies are needed to alleviate vaccine hesitancy in this vulnerable group.
Keywords: COVID-19, Vaccine, Inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn’s disease (CD)
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
